New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
09:08 EDTHWD, AET, ABMD, SWHC, AMRN, BAGLOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Smith & Wesson (SWHC), up 3.9%... ALSO HIGHER: Einstein Noah (BAGL), up 8.9% after declaring $4.00 special dividend... Aetna (AET), up 1.2% after JPMorgan upgrades to Overweight... LOWER AFTER EARNINGS: Harry Winston (HWD), down 2.9%... ALSO LOWER: Amarin (AMRN), down 19.1% after announcing non-equity financing, saying continues to assess strategic alternatives... ABIOMED (ABMD), down 5.8% after an FDA panel voted to retain Class III status for certain pumps, including its Impella.
News For AET;BAGL;SWHC;HWD;AMRN;ABMD From The Last 14 Days
Check below for free stories on AET;BAGL;SWHC;HWD;AMRN;ABMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:05 EDTABMDAbiomed acquires exclusive license for Opsens' optical sensor technology
Abiomed announced its acquisition of an exclusive license from collaboration partner Opsens. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab. This licensing agreement, which secures Abiomed's rights to the technology and gives Abiomed the right to manufacture the sensors, is a continuation of an initial collaboration, entered into between Opsens and Abiomed in 2010.
06:32 EDTAETPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
10:05 EDTAETAetna, Tenet form accountable care collaboration in San Antonio
Aetna (AET), Tenetís (THC) Baptist Health System and HealthTexas Medical Group announced an accountable care collaboration and the introduction of the Aetna Whole Health product in the San Antonio area. The health plans, designed for fully insured customers with employees who live or work in Bexar, Guadalupe, Comal and Kendall counties, will be available on July 1.
April 10, 2014
07:34 EDTABMDAbiomed shares attractive following recent weakness, says Stephens
Stephens believes Abiomed shares are attractively valued following their recent weakness given the stock's valuation relative to peers. The firm says Abiomed remains one of its top ideas and reiterates its Overweight rating and $34 price target on the stock.
April 8, 2014
10:18 EDTAETCMS says Medicare Advantage reimbursement to rise in 2015
Subscribe for More Information
09:23 EDTAETLeerink views final rates as favorable for MA plans
Subscribe for More Information
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
April 7, 2014
19:13 EDTAETCMS issues 2015 rate announcement for Medicare Advantage and Part D programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use